SCHEDULE: Robert Duggan Increases Stake in Pulse Biosciences

Robert W. Duggan has increased his beneficial ownership in Pulse Biosciences, Inc. to approximately 71.9% following recent share acquisitions.

Summary

• Robert W. Duggan, through personal holdings and controlled entities, now beneficially owns 49,706,423 shares of Pulse Biosciences, Inc.
• The total ownership stake represents approximately 71.9% of the company's outstanding common stock.
• The increase in holdings includes the acquisition of 660,233 shares purchased through the company's at-the-market (ATM) equity offering program.
• The shares were acquired at a price of $19.69 per share on May 11, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal regarding internal confidence, though the high concentration of ownership and ongoing dilution via ATM offerings warrant caution for minority investors.

Positives

• Strong demonstration of insider confidence with a significant capital commitment of approximately $13 million for the recent 660,233 share purchase.
• Consolidation of control by a major shareholder, which may provide stability in strategic direction.

Negatives

• High concentration of ownership (71.9%) by a single individual may limit the influence of minority shareholders.
• The acquisition was facilitated through an at-the-market offering, which results in dilution for existing shareholders.

Risks

• Potential for reduced liquidity in the company's common stock due to the high concentration of ownership.
• Market sensitivity to the actions and decisions of a single controlling shareholder.

Future Outlook

The filing does not provide specific forward-looking operational guidance, but indicates continued participation in the company's equity financing activities.

Management Comments

• The reporting person certifies that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that significant insider accumulation in the medical technology sector often signals management's belief in the success of upcoming clinical milestones or commercialization efforts, despite the dilutive nature of ATM offerings.

Comparison to Industry Standards

• The level of insider ownership at 71.9% is significantly higher than the average for publicly traded medical device companies, which typically see lower founder/insider concentration.
• The use of at-the-market offerings is a standard capital-raising mechanism for growth-stage biotech and medtech firms to fund R&D and commercial expansion.

Corporate Governance

Related Party Transactions

• Disclosure of shares held by Genius 24C Inc and Blazon Corporation, both of which are controlled by Robert W. Duggan.

Stakeholder Impact

• Shareholders may experience dilution from the ATM offering program.
• The concentration of voting power significantly impacts the influence of other shareholders in corporate governance matters.

Next Steps

• Continued monitoring of the company's at-the-market equity offering program.
• Observation of future SEC filings for potential changes in beneficial ownership.

Key Dates

Recommendation

While insider buying is a strong bullish signal, the extreme concentration of ownership and the reliance on equity dilution to fund operations suggest a hold position until further commercial progress is demonstrated.

Keywords

Pulse Biosciences, Robert Duggan, Schedule 13D, Insider Ownership, Equity Offering, PLSE